[PDF] Top 20 Formação docente na era da cibercultura
Has 10000 "Formação docente na era da cibercultura" found on our website. Below are the top 20 most common "Formação docente na era da cibercultura".
A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
... single-arm study, we enrolled the refractory mCRC patients who received fluoropyrimidine, oxaliplatin, and irinotecan treatment and at least one targeted therapy ...enrolled patients, 36 ... See full document
7
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
... for patients receiving bevacizumab plus mFOLFOX6 as first-line treatment was 10 months and that a 40% improvement in median progression-free survival (14 months) in the sunitinib arm was clinically ...290 ... See full document
9
Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
... broad-spectrum oral multikinase inhibitor that targets several angiogenic, oncogenic, and stromal receptor tyrosine kinases that support the tumor ...pivotal Phase III Patients with Metastatic ... See full document
46
Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
... consecutive patients with mCRC were treated with bevacizumab plus chemotherapy (mainly oxaliplatin- or irinotecan-containing regimens) as a third- or later-line ...or 1 in 97.2% of the ... See full document
8
Rationale and Study Protocol of the J SAVER Study: A Phase II Study of S 1 on Alternate Days Combined with Bevacizumab in Patients Aged ≥75 Years with Metastatic Colorectal Cancer
... Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide [1], and the mortality from CRC among all cancers in Japan is the third highest for men and the ... See full document
290
<p>Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer</p>
... multicenter, phase III study to con fi rm the ef fi - cacy and safety of adding cetuximab to fi rst-line fl uorouracil, leucovorin and oxaliplatin (FOLFOX-4) in patients with RAS wt ...cetuximab ... See full document
97
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
... In phase I trials, fruquintinib demonstrated good pharmacokinetic prop- erties, tolerable safety, and promising anti-tumor activity against multiple tumor types ...comparison study was carried out [14], and ... See full document
465
Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX
... for patients with advanced pancreatic cancer; however, there are still no biomarkers to predict favorable outcomes of the ...for metastatic colorectal cancer [4–7]. The phase III ... See full document
113
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
... multidisciplinary colorectal cancer team at Cancer Institute Hospital, Tokyo, Japan, confirmed patient ...all patients every 2 weeks or before each treatment ...the study, and tumor ... See full document
14
A Multicenter Cohort Study for XELOX (Capecitabine, Leucovorin plus Oxaliplatin) Therapy as First Line Treatment in Elderly Patients with Unresectable Colorectal Cancer
... 107 patients were enrolled in this study, consisting of 55 non-elderly patients who were <70 years of age and 52 elderly patients who were ≥70 years of ...and treated patients ... See full document
74
Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
... 40 patients from four hospitals were ...Table 1. The median age was 56 years (range 21–79 years), and most patients were men (n = 27, ...(57.5%) patients had colon can- cer. All ... See full document
27
<p>Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects</p>
... the patients had Grade 3 or higher toxicity; most commonly palmar-plantar erythrody- sesthesia (PPE), hypertension, fatigue and diarrhea; dose modi fi cation was required in over 70% of the ...” phase 2 ... See full document
7
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
... while serious complications are only infrequently reported or not at all. This process runs the risk that no discipline feels responsible for their recognition. However, it is currently the oncologist as treating ... See full document
5
The molecular pathogenesis of head and neck squamous cell carcinoma
... Squamous cell carcinoma of the head and neck (HNSCC) is a relatively common human cancer characterized by high morbidity, high mortality, and few therapeutic options outside of surgery, standard cytotoxic ... See full document
7
Role of oxaliplatin in the treatment of colorectal cancer
... Cytotoxic lesions produced by oxaliplatin are the formation of intra-strand and inter-strand platinum-DNA adducts, formed by cross-linking between activated plati- num species and specifi c base sequences, mainly two ... See full document
29
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
... protein 1 (PD-1), is currently recruit- ing patients with advanced solid tumors ...in patients with advanced melanoma, non-small cell lung cancer, and castrate-resistant prostate ... See full document
5
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first line setting: study protocol for a randomized controlled trial
... LV plus an irinotecan-based regimen (FOLFIRI) with bevacizumab has been widely used as a first-line treatment for patients with mCRC ...mCRC patients and resulted in satis- factory therapeutic ... See full document
7
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
... Abstract: Colorectal cancer is considered a disease of the elderly ...geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent ...of ... See full document
30
Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM)
... Figure 1 Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease, ... See full document
92
Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
... 112 patients with histopathologically confirmed mCRC treated with first-line FOLFOX/XELOX in combina- tion with Bev and second-line FOLFIRI with C-mab (N = 42) or Bev (N = 70) were enrolled between October ... See full document
5
Related subjects